EGF Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: epithelial growth and wound models

Cosmetic Research protein LyophilizedLiquid verified

Also known as: Epidermal growth factor

Quick Facts

Reference Sizes
100 mcg, 1 mg
Calculator
Preset available
Storage
Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.
Solubility
Water-soluble; usually formulated as aqueous serum or cream; HA conjugation improves stability and penetration

Catalog Description

EGF (Epidermal Growth Factor) is a single-chain 53-amino-acid polypeptide, first isolated from the submaxillary glands of mice, that stimulates epidermal cell proliferation and keratinization both in vitro and in vivo - foundational biology underlying its use in wound-healing and cosmetic skin-regeneration research and products.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Approximately 1 minute or less in human plasma, based on studies of rapid blood clearance; ocular/tissue studies report longer local half-lives in the 0.6-1.9 hour range depending on tissue.
Onset
Cell-proliferation effects measurable within days in vitro; clinical skin outcomes over weeks
Administration Routes (Research)
TopicalLocal / intralesionalLaboratory / preclinical

Reported Research Effects

Reported Research Side Effects

Data source: Randomized human topical and intralesional studies plus formulation literature

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Topical Human study only

0.005% recombinant human EGF spray twice daily

Frequency / timing
Twice daily
Duration / setting
Up to 12 weeks
Technique
Topical
Evidence
Human study protocol

Context: Phase 3 randomized trial PMID 29902542

Formulation: Concentration, vehicle, treated area, and product sterility are formulation-specific.

Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.

Local / intralesional Not established

No route-specific amount established in the reviewed record.

Technique
Intralesional in specific clinical studies
Evidence
Route noted; protocol not established

Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.

Laboratory / preclinical Preclinical only

No route-specific amount established in the reviewed record.

Technique
Laboratory use
Evidence
Route noted; protocol not established

Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.

Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Clinical wound studies used defined recombinant formulations such as 0.005% spray. Cosmetic serums and raw RUO EGF are not interchangeable with those products; community DIY-mixing claims are anecdotal.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Topical rhEGF spray Phase 3 trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/29902542/
Intralesional rhEGF randomized trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/20051095/
EGF-CMC hydrogel randomized trial — PubMed Central (NIH)
https://pmc.ncbi.nlm.nih.gov/articles/PMC9957415/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Articles

Published articles on this site that mention EGF or one of its catalog aliases.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top